New York-based Regeneron Pharmaceuticals Inc Stock Performs Better

Regeneron Pharmaceuticals Inc. Shares inched 0.61% higher to $528.75 Monday. This proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.18% to 4,255.15 and the Dow Jones Industrial Average DJIA falling 0.25% to 34,393.75.Regeneron Pharmaceuticals Inc. closed $135.89 below its 52-week high ($664.64), which the company reached on July 20th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson JNJ rose 0.25% to $165.37, Novartis AG ADR NVS rose 0.97% to $93.59, and Amgen Inc. AMGN fell 0.65% to $241.19.

Regeneron Pharmaceuticals Inc. trading volume (497,814) remained 289,969 below its 50-day average volume of 787,783. At last year’s advisory vote on executive pay, which is held every three years, Regeneron’s plans received support from 70.1% of votes cast. At the time of the meeting, Schleifer owned 16.6% of the company while the French drugmaker Sanofi had a 20.6% holding, which it has since sold. When these stakes are excluded, less than 33% of votes were cast in favour of the company’s pay plans.

Regeneron is supplying the US government with millions of doses of its Covid antibody cocktail REGEN-COV, after receiving emergency authorisation for the treatment in November. It is a combination of two monoclonal antibodies designed to prevent the coronavirus spike protein attaching to receptors in the body, to prevent Sars-CoV-2 infection and to treat people who have contracted the virus.

The share price of the Nasdaq- and London-listed company soared in early October 2020, from $564 to over $600 a share, after then-president Trump touted the treatment in a video, claiming that it had cured his Covid. The shares have risen 41% since the start of 2020.